Bio-Path (NASDAQ:BPTH) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002.
This clinical trial is focusing on the use of BP1002 as a treatment for refractory/relapsed acute myeloid leukemia (AML). It’s focusing on patients with AML and patients who are venetoclax resistant.
Bio-Path is currently testing the “dose escalation portion” of its Phase 1/1b study. The company notes that it has successfully completed its second dose cohort in this process.
Bio-Path CEO Peter Nielsen said the following about this progress:
“Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.”
BPTH Stock Movement Today
News of the clinical trial progress brings with it heavy trading of BPTH stock today. That has more than 40 million shares changing hands as of this writing. This is well above its daily average trading volume of about 40,000 shares.
BPTH stock is up 89.1% as of Thursday morning. However, the shares are still down 38.7% since the start of the year.
Investors seeking out even more of the most recent stock market stories will want to stick around!
We have all of the hottest stock market news traders need to know about on Thursday! A few examples include what’s happening with shares of AGBA Group (NASDAQ:AGBA), Tesla (NASDAQ:TSLA) and NRX Pharmaceuticals (NASDAQ:NRXP) stock today. All of that info is ready to go below!
More Stock Market News for Thrusday
- Why Is AGBA Group (AGBA) Stock Up 149% Today?
- Deutsche Just Slashed Its Price Target on Tesla (TSLA) Stock
- Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
